RETRACTED: LSAMP-AS1 binds to microRNA-183-5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN (Retracted article. See vol. 72, 2021)

被引:23
|
作者
Hua, Xing [1 ]
Liu, Zhen [2 ]
Zhou, Min [3 ]
Tian, Yan [4 ,5 ,6 ]
Zhao, Pei-Pei [4 ,5 ,6 ]
Pan, Wen-Hai [1 ]
Li, Chao-Xia [1 ]
Huang, Xiao-Xiao [1 ]
Liao, Ze-Xiao [1 ]
Xian, Qi [1 ]
Chen, Bo [1 ]
Hu, Yue [1 ]
Leng, Lei [1 ]
Fang, Xiao-Wei [1 ]
Yu, Li-Na [4 ,5 ,6 ]
机构
[1] Jinan Univ, Med Coll, Guangzhou Red Cross Hosp, Dept Pathol, Guangzhou 510220, Guangdong, Peoples R China
[2] Guizhou Med Univ, Sch Basic Med Sci, Dept Pathol, Guiyang 550025, Guizhou, Peoples R China
[3] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Otolaryngol, Guangzhou 510006, Guangdong, Peoples R China
[4] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, 1838 North, Guanghou 510515, Peoples R China
[5] Nanfang Hosp, Dept Pathol, Guanghou 510515, Peoples R China
[6] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China
来源
EBIOMEDICINE | 2019年 / 50卷
基金
中国国家自然科学基金;
关键词
Prostate cancer; LSAMP-AS1; MicroRNA-183-5p; Decorin; Epithelial-mesenchymal transition; Proliferation Migration; CELL-PROLIFERATION; EXPRESSION; MARKERS; LNCRNA; COMPLICATIONS; STATISTICS; MIGRATION; SURVIVAL; DECORIN; GROWTH;
D O I
10.1016/j.ebiom.2019.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: : Prostate cancer (PCa) is a leading cause of cancer-related death in males. Aberrant expression of long noncoding RNAs (lncRNAs) is frequently reported in human malignancies. This study was performed to explore the role of LSAMP-AS1 in epithelial-mesenchymal transition (EMT), proliferation, migration and invasion of PCa cells. Methods: : Initially, the differentially expressed lncRNAs in PCa were screened out by microarray analysis. The clinicopathological and prognostic significance of LSAMP-AS1 was evaluated. LSAMP-AS1 was over-expressed or silenced to investigate the roles in EMT, proliferation, migration and invasion of PCa cells. Moreover, the relationships between LSAMP-AS1 and miR-183-5p, as well as miR-183-5p and decorin (DCN) were characterized. The tumorigenicity of PCa cells was verified in nude mice. Results: : LSAMP-AS1 was poorly expressed in PCa tissues and cells. Low expression of LSAMP-AS1 was indicative of poor overall survival and disease-free survival, and related to Gleason score, TNM stage, and risk stratification. Over-expressed LSAMP-AS1 inhibited EMT, proliferation, migration and invasion of PCa cells, as well as tumor growth in nude mice. Meanwhile, over-expression of LSAMP-AS1 resulted in up-regulation of E-cadherin and down-regulation of Vimentin, N-cadherin, Ki67, PCNA, MMP-2, MMP-9, Ezrin and Fascin. Notably, LSAMP-AS1 competitively bound to miR-183-5p which directly targets DCN. It was confirmed that the inhibitory effect of LSAMP-AS1 on PCa cells was achieved by binding to miR-183-5p, thus promoting the expression of DCN. Conclusion: : LSAMP-AS1 up-regulates the DCN gene by competitively binding to miR-183-5p, thus inhibiting EMT, proliferation, migration and invasion of PCa cells. (C) 2019 The Author(s). Published by Elsevier B.V.
引用
收藏
页码:178 / 190
页数:13
相关论文
共 50 条
  • [1] RETRACTION: LSAMP-AS1 binds to microRNA-183-5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN (Retraction of Vol 50, Pg 178, 2019)
    Hua, Xing
    Liu, Zhen
    Zhou, Min
    Tian, Yan
    Zhao, Pei-Pei
    Pan, Wen-Hai
    Li, Chao-Xia
    Huang, Xiao-Xiao
    Liao, Ze-Xiao
    Xian, Qi
    Chen, Bo
    Hu, Yue
    Leng, Lei
    Fang, Xiao-Wei
    Yu, Li-Na
    EBIOMEDICINE, 2021, 72
  • [2] RETRACTED: CircLMTK2 acts as a tumor suppressor in prostate cancer via regulating the expression of microRNA-183 (Retracted article. See vol. 256, 2020)
    Jin, Chengjun
    Zhao, Weiming
    Zhang, Zijian
    Liu, Wanpeng
    LIFE SCIENCES, 2020, 241
  • [3] RETRACTED: MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2 (Retracted article. See vol. 25, pg. 2156, 2021)
    Pan, M-Z
    Song, Y-L
    Gao, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (20) : 8795 - 8805
  • [4] RETRACTED: MicroRNA-154 functions as a tumor suppressor in osteosarcoma by targeting Wnt5a (Retracted article. See vol. 46, 2021)
    Zhou, Hui
    Zhang, Minglei
    Yuan, Hongping
    Zheng, Wei
    Meng, Chunyan
    Zhao, Dongxu
    ONCOLOGY REPORTS, 2016, 35 (03) : 1851 - 1858
  • [5] RETRACTED: A glycolytic mechanism regulating an angiogenic switch in prostate cancer (Retracted article. See vol. 81, pg. 1623, 2021)
    Wang, Jianhua
    Wang, Jincheng
    Dai, Jinlu
    Jung, Younghun
    Wei, Chuen-Long
    Wang, Yu
    Havens, Aaron M.
    Hogg, Phillip J.
    Keller, Evan T.
    Pienta, Kenneth J.
    Nor, Jacques E.
    Wang, Cun-Yu
    Taichman, Russell S.
    CANCER RESEARCH, 2007, 67 (01) : 149 - 159
  • [6] RETRACTED: Thermal Preconditioning May Prevent Tendon Adhesion by Up-Regulating HSP72 in Rats (Retracted article. See vol. 55, pg. 664, 2021)
    Tan, Yang
    Wu, Qin-Fen
    Wu, Qiang
    Tan, Xin-Ti
    Chen, Liao-Bin
    Wang, Xin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 42 (04) : 1623 - 1634
  • [7] RETRACTED: MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma (Retracted article. See vol. 46, 2021)
    Zhang, Shoulin
    Zhang, Dongmei
    Yi, Chunguang
    Wang, Yinping
    Wang, Hongan
    Wang, Jian
    ONCOLOGY REPORTS, 2016, 35 (01) : 559 - 567
  • [8] RETRACTED: MicroRNA-491-5p suppresses cervical cancer cell growth by targeting hTERT (Retracted article. See vol. 46, 2021)
    Zhao, Qiang
    Zhai, Ying-Xian
    Liu, Huan-Qiu
    Shi, Ying-Ai
    Li, Xin-Bai
    ONCOLOGY REPORTS, 2015, 34 (02) : 979 - 986
  • [9] RETRACTED: MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma (Retracted article. See vol. 22, 2021)
    Zhou, Zheng
    Li, Zhihong
    Shen, Yi
    Chen, Tao
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 14 (04) : 3665 - 3673
  • [10] RETRACTED: MicroRNA-137 acts as a tumor suppressor in osteosarcoma by targeting enhancer of zeste homolog 2 (Retracted article. See vol. 22, 2021)
    Feng, Qiong
    Wu, Qing
    Liu, Xing
    Xiong, Yanfei
    Li, Hui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (06) : 3167 - 3174